FORMA Therapeutics is integrating transformative chemistry and biology to unlock the best targets and pathways that genomic medicine has revealed. FORMA is building on the scientific vision of its academic founders: Stuart Schreiber, Todd Golub and Mike Foley, all of the Broad Institute of Harvard and MIT.
FORMA is a global company headquartered in Cambridge, MA with additional research operations in Connecticut, Singapore and Beijing.